Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Genentech to Present on Various Therapies at ASCO

By Drug Discovery Trends Editor | May 19, 2011

Genentech reported that data showing new personalized approaches for skin and lung cancer patients, plus new data with Avastin (bevacizumab) in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 3-7. 

Roche and Genentech’s investigational and approved cancer medicines will be featured in approximately 300 abstracts across more than 30 cancer types.
 
“Our goal is to develop cancer medicines that improve care in a way that is meaningful to patients and their doctors,” said Hal Barron, MD, chief medical officer and head of global product development.

Data from a Phase III study (BRIM3) testing Vemurafenib  (RG7204/PLX4032) in people with previously untreated metastatic melanoma with a mutated BRAF gene will be presented for the first time, as will an  Updated Phase II data (BRIM2).

Data from EURTAC, the first Phase III study of Tarceva compared with chemotherapy in a Western population of people who had not previously been treated for a genetically distinct form of advanced lung cancer will be presented, as will MetMAb, a randomized Phase II data comparing MetMAb plus Tarceva to placebo plus Tarceva in people with advanced lung cancer with high or low levels of the Met receptor (Met diagnostic-positive or -negative).

Avastin, a Phase III data (OCEANS) in women with ovarian cancer that has progressed following initial treatment with platinum-based chemotherapy will be presented for the first time.  New analyses from the Phase III ICON7 study in women with newly diagnosed ovarian cancer and with poor prognosis will also be presented.
 
Release Date: May 17, 2011
Source: Genentech  


Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE